人民财讯1月25日电，方盛制药（603998）1月25日公告，1月23日，公司全资子公司健盟药业收到国家 药品监督管理局核准签发的《药品注册证书》，洛索洛芬钠凝胶贴膏已获得药品批准文号并可进行生 产。洛索洛芬钠凝胶贴膏适用于骨关节炎、肌肉痛及外伤后的肿胀疼痛的消炎、镇痛，有效成分为洛索 洛芬钠，属苯丙酸类非甾体抗炎药(NSAID)，具有显著的抗炎镇痛作用，尤以镇痛效果为强。 ...

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 洛索洛芬钠凝胶贴膏适用于骨关节炎、肌肉痛及外伤后的肿 胀疼痛的消炎、镇痛，有效成分为洛索洛芬钠，属苯丙酸类非甾 第 1页，共 3页 药品名称 洛索洛芬钠凝胶贴膏 受理号 CYHS2402679 证书编号 2026S00080 主要成分 洛索洛芬钠 剂型 贴膏剂 申请事项 药品注册（境内生产） 规格 每贴（14cm×10cm）含膏体 10g，含洛索洛芬钠 100mg（按 C15H17NaO3计） 注册分类 化学药品 4 类 药品注册标准编号 YBH34292025 药品批准文号 国药准字 H20263068 药品批准文号有效期 至 2031 年 1 月 13 日 上市许可持有人 广东方盛健盟药业有限公司 生产企业 湖南方盛制药股份有限公司 审批结论 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 一、《药品注册证书》主要内容 证券代码：603998 证券简称：方盛制药 公告编号：2026-005 湖南方盛制药股份有限公司 关于洛索洛芬钠凝胶贴膏获得《 ...

每经AI快讯，方盛制药1月25日晚间发布公告称，2026年1月23日，湖南方盛制药股份有限公司全资子 公司广东方盛健盟药业有限公司收到国家药品监督管理局核准签发的《药品注册证书》，洛索洛芬钠凝 胶贴膏已获得药品批准文号并可进行生产。 每经头条（nbdtoutiao）——丹麦士兵荷枪实弹上岛，准备战斗！反击特朗普夺岛图谋，美最大债主3.6 万亿美元"金融核弹"可随时引爆，格陵兰风云骤起 （记者 王晓波） ...

2026年1月22日 湖南方盛制药股份有限公司（以下简称"公司"）全资子公司云南芙雅生物科技有限公司（以下简称"芙 雅生物"）于近日收到由云南省科学技术厅、云南省财政厅、国家税务总局云南省税务局联合颁发的 《高新技术企业证书》被认定为高新技术企业。证书编号为GR202553000493，有效期三年。 根据国家相关规定，本次通过高新技术企业认定后，芙雅生物将连续三年享受国家关于高新技术企业的 所得税优惠政策，即按15%的税率缴纳企业所得税，本次芙雅生物通过高新技术企业认定事项不会对公 司当期经营业绩产生重大影响。 芙雅生物此次被认定为高新技术企业，有利于进一步提升创新能力、增强市场竞争力。 特此公告 证券代码：603998 证券简称：方盛制药 公告编号：2026-004 湖南方盛制药股份有限公司 关于全资子公司再次被认定为高新技术企业的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司董事会 ...

根据国家相关规定，本次通过高新技术企业认定后，芙雅生 物将连续三年享受国家关于高新技术企业的所得税优惠政策，即 按15%的税率缴纳企业所得税，本次芙雅生物通过高新技术企业 认定事项不会对公司当期经营业绩产生重大影响。 证券代码：603998 证券简称：方盛制药 公告编号：2026-004 湖南方盛制药股份有限公司 关于全资子公司再次被认定为高新技术企业的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）全资子公 司云南芙雅生物科技有限公司（以下简称"芙雅生物"）于近日 收到由云南省科学技术厅、云南省财政厅、国家税务总局云南省 税务局联合颁发的《高新技术企业证书》被认定为高新技术企业。 证书编号为GR202553000493，有效期三年。 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 芙雅生物此次被认定为高新技术企业，有利于进一步提升创 新能力、增强市场竞争力。 特此公告 湖南方盛制药股份有限公司董事会 2026年1月22 ...

根据国家相关规定，本次通过高新技术企业认定后，芙雅生物将连续三年享受国家关于高新技术企业的 所得税优惠政策，即按15%的税率缴纳企业所得税，本次芙雅生物通过高新技术企业认定事项不会对公 司当期经营业绩产生重大影响。 格隆汇1月22日丨方盛制药(603998.SH)公布，公司全资子公司云南芙雅生物科技有限公司于近日收到由 云南省科学技术厅、云南省财政厅、国家税务总局云南省税务局联合颁发的《高新技术企业证书》被认 定为高新技术企业。证书编号为GR202553000493，有效期三年。 ...

Core Viewpoint - The innovative traditional Chinese medicine "Yangxue Qufeng Zhitong Granules," developed by Guang Dong Fangsheng Jianmeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Hunan Fangsheng Pharmaceutical Co., Ltd., has been successfully included in the Guangzhou Innovation Drug and Medical Device Product Directory [1] Company Summary - Hunan Fangsheng Pharmaceutical Co., Ltd. has a subsidiary named Guang Dong Fangsheng Jianmeng Pharmaceutical Co., Ltd. that focuses on the development of innovative traditional Chinese medicine [1] - The company has achieved a significant milestone with its product being recognized in a prominent innovation directory, indicating potential growth and recognition in the pharmaceutical industry [1] Industry Summary - The event held in Huangpu District, Guangzhou, focused on the high-quality development of the biopharmaceutical and health industry, highlighting the importance of innovation in this sector [1] - The inclusion of the product in the innovation directory reflects the growing emphasis on innovative healthcare solutions within the biopharmaceutical industry in Guangzhou [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998) has received a notice from the Hunan Provincial Drug Administration regarding non-compliance in a GMP inspection of its production site for the active pharmaceutical ingredient Indobufen, which is currently in the pre-market preparation stage [1] Group 1: Inspection Results - The inspection conducted in November 2025 concluded that the production site in the Wangcheng Economic Development Zone did not meet the required standards due to outdated production standards for intermediate 1 [1] - The inspection specifically focused on the production line for Indobufen and related processes [1] Group 2: Regulatory Approval and Market Readiness - Indobufen received approval for market launch in June 2024, but the product has not yet been officially released for sale [1] - The company is in the process of rectifying the issues identified during the inspection and plans to reapply for the inspection promptly [1]

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced a special cash dividend of 0.15 RMB per share for the fiscal year 2025, totaling approximately 65.86 million RMB, following the approval from the shareholders' meeting and the board of directors [1][3]. Dividend Distribution Plan - The special dividend is based on a total share capital of 439,081,360 shares, with a cash distribution of 0.15 RMB per share, amounting to a total cash dividend of 65,862,204 RMB [3]. - The dividend will be distributed to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [2]. Implementation Details - The cash dividends will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited, with shareholders who have completed designated transactions able to receive their dividends on the payment date [4]. - For shareholders who have not completed designated transactions, the dividends will be held by China Securities Depository and Clearing Corporation Limited until the transactions are completed [4]. Taxation Information - For individual shareholders holding unrestricted A-shares, the tax treatment varies based on the holding period: - Holding period within 1 month: 20% tax on dividends - Holding period between 1 month and 1 year: 10% effective tax rate - Holding period over 1 year: exempt from personal income tax [6][7]. - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.135 RMB per share [8]. Compliance and Inspection - The company received a non-compliance notice from the Hunan Provincial Drug Administration regarding the production of the raw material indobufen, due to outdated standards during the production process [10]. - The company is currently in the preparation stage for the market launch of indobufen and has initiated corrective actions to address the issues identified during the inspection [11].